Filing Flows

Filing Flows › Companies › TG Therapeutics › Cash flow

TG Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$39.0M in Q2 2026 · $17.4M over twelve months

Operating cash flow$39.3M
Capital spending−$293K
Free cash flow+$39.0M
Cash / net income5.0×
Cash conversion cycle56 days

Analysis

In Q2 2026, TG Therapeutics generated $39.3M of operating cash flow and spent $293K on capital projects, leaving free cash flow of $39.0M. That is $31.6M more than in Q2 2025 ($7.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was $17.9M; the largest uses were other financing ($258M), buybacks ($178M), capital spending ($491K); besides operations, cash came from net borrowing (+) / repaid (−) ($748M), other investing ($22.4M); the cash balance rose by $353M.

Operating cash flow was $39.3M against net income of $7.8M — 5.0× profit, cash ran ahead of reported earnings. The largest differences: inventory −$66.8M, payables +$65.3M, stock-based pay +$27.9M.

Its cash conversion cycle was 56 days (receivables 150 + inventory 306 − payables 400).

Free cash flow

TG Therapeutics: free cash flow by quarterTG Therapeutics: free cash flow by quarter−$12.2MQ3 2024−$25.7MQ4 2024−$28.7MQ1 2025$7.4MQ2 2025−$23.2MQ3 2025$19.6MQ4 2025−$17.9MQ1 2026$39.0MQ2 2026
Operating cash flow less capital spending.
TG Therapeutics: operating cash flow against capital spendingTG Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$12.2M$24KQ3 2024−$25.6M$21KQ4 2024−$28.7M$25KQ1 2025$7.4M$42KQ2 2025−$23.2M$80KQ3 2025$19.7M$67KQ4 2025−$17.9M$51KQ1 2026$39.3M$293KQ2 2026
Latest (Q2 2026): Operating cash flow $39.3M, Capital spending $293K.

Capital allocation, year by year

TG Therapeutics: where the cash came from (up) and went (down), by fiscal yearTG Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow −$296MFY2021: Net borrowing $70.0MFY2021: Shares issued $2.4MFY2021: Capital spending −$401K$72.4MFY2021FY2022: Operating cash flow −$176MFY2022: Shares issued $584KFY2022: Capital spending −$14K$584KFY2022FY2023: Operating cash flow −$31.4MFY2023: Net borrowing $25.0MFY2023: Shares issued $47.8M$72.8MFY2023FY2024: Operating cash flow −$40.5MFY2024: Net borrowing $245MFY2024: Shares issued $914KFY2024: Capital spending −$45KFY2024: Buybacks −$8.8M$246MFY2024FY2025: Operating cash flow −$24.8MFY2025: Shares issued $1.5MFY2025: Capital spending −$214KFY2025: Buybacks −$91.2M$1.5MFY2025
Over these 5 years operating cash flow totalled −$569M; the largest uses were operating cash flow ($569M) and buybacks ($100M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$552M
Debt$745M
Net debt$193M

TG Therapeutics funds itself: free cash flow was $17.4M over the last twelve months, and $552M of cash and investments stands against $745M of debt.

Where the cash came from and went

TG Therapeutics: sources (+) and uses (−) of cash, Q2 2026TG Therapeutics: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)−$40.4MOperating cash flow$39.3MOther investing$1.3MCapital spending−$293KShares issued$85K
TG Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026TG Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Net borrowing (+) / repaid (−)$748MCash drawn (+) / kept (−)−$353MOther financing−$258MBuybacks−$178MOther investing$22.4MOperating cash flow$17.9MShares issued$1.9MCapital spending−$491K

From profit to cash

TG Therapeutics: net income to operating cash flow, Q2 2026TG Therapeutics: net income to operating cash flow, Q2 2026Net income$7.8MDepreciation & amortization$53KStock-based pay$27.9MDeferred taxes$708KReceivables−$9.5MInventory−$66.8MPayables$65.3MDeferred revenue$7.3MPrepaid and other assets$13.6MOther liabilities−$262KIncome taxes payable−$6.1MOperating cash flow$39.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202615030640056
Q1 2026153342344151
Q4 2025136329265200
Q3 2025141495403233
Q2 2025136752644244
Q1 2025119777557339
Q4 2024104583477210
Q3 2024109817960-33

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026$39.3M−$293K——$85K−$40.4M$39.0M
Q1 2026−$17.9M−$51K−$100M$748M$763K−$363M−$17.9M
Q4 2025$19.7M−$67K——$1.1M−$5.1M$19.6M
Q3 2025−$23.2M−$80K−$78.2M——$55.0M−$23.2M
Q2 2025$7.4M−$42K−$6.9M—$432K$3.0M$7.4M
Q1 2025−$28.7M−$25K−$6.1M—$21K$47.8M−$28.7M
Q4 2024−$25.6M−$21K−$6.6M—$570K$15.9M−$25.7M
Q3 2024−$12.2M−$24K−$2.1M$245M$199K−$113M−$12.2M

TG Therapeutics: income statement and cash flow

TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%. The chart follows the revenue to costs, profit and cash.

TG Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.